Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Herceptin Biosimilar Moving Forward Amid Rising Competition

Executive Summary

Pfizer hopes positive top-line Phase III trial data on its Herceptin (trastuzumab) biosimilar can help it tap the lucrative market in HER2-overexpressing cancers, but analysts say that therapeutic space looks increasingly crowded with no clear favorite yet in sight.

Advertisement

Related Content

Mylan Clears Runway For US Herceptin Biosimilar Launch
Buoyant Biocon Bullish On US Biosimilar Interchangeability
Pfizer Essential Health Is Staying Put And Has A Focused Strategy For Growth
Keeping Track: Mylan Submits Biosimilar Herceptin; FDA Clears Opdivo For Head And Neck Cancer
Biocon Confident As First Biosimilars Seen Hitting Europe In Early 2018
Celltrion's Biosimilar Strategy Includes Simultaneous EMA/FDA Reviews
Pfizer/Hospira's Biosimilar Pipeline: Substantial Overlap, Limited Divestiture So Far

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097777

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel